


Your competent partner
in oncology and hemostaseology.



Specialized Immunology
Research and Development GmbH

In association with
Transfusion Medicine Center
Bayreuth (TZB)

Kurpromenade 2
95448 Bayreuth, Germany
Phone: +49 (0) 921 730052
mail@simfo.com
www.simfo.com

Specialized Medical Laboratory
Dr. Pachmann

Kurpromenade 2
95448 Bayreuth, Germany
Phone: +49 (0) 921 850200

Since 2005, maintrac is performed by the DIN
EN ISO 15189 accredited specialized medical
laboratory Dr. Pachmann.

180625-FLAL-EN-WM

maintrac



maintrac guides you through
cancer therapy.




maintrac

maintrac diagnostics - prior, during and
after cancer therapy.

Each cancer is different and treatment effectiveness can vary.
Therefore, it is important to monitor the success of the therapies
applied.

**Cancer releases tumor cells - circulating tumor cells - into
the blood.** Even years after surgery or therapy tumor cells can still
be present in the blood. The tumor cells are able to change during
the course of disease. These cells can be responsible for recurrence
of the cancer. Early detection of these changes allows you to
receive the right therapy at the right time.



maintrac is a highly sensitive diagnostic method based on
circulating tumor cells. It allows a direct glance at tumor activity.

maintrac can test different medications directly on circulating
tumor cells before therapy. This yields information about the
therapy effectiveness in advance.

maintrac permits the identification of therapy-relevant properties
of the tumor cells. Tailoring of the therapy is possible at any time.

maintrac uses circulating tumor cells to monitor the therapy and
the follow-up in order to early track any changes, already in the
primary situation.


Is the current therapy effective?
Is there a risk of suffering from relapse?

These are key questions for patients.
maintrac helps to answer these questions.

We need 15ml of EDTA blood for the analysis.

maintrac has the following advantages,
already in the primary situation:

- Early recognition of renewed tumor activity
- Control of the therapy
- Tailoring of the therapy
- Longtime monitoring after the end of therapy



Picture above:
Living tumor cells are stained green in the blood test.
Dead tumor cells have an additional red staining.

maintrac – monitoring tumor activity

Is it possible to determine whether treatment is or was successful?

maintrac can detect tumor activity based on increasing numbers of tumor cells in the blood, usually sooner than other methods.

maintrac is an additional tool for the physician to regularly monitor tumor activity (every 3 - 6 months).

In case of increasing cell numbers, the cancer therapy should be modified.



maintrac – testing of medications

Which substances will work for the patient?


The daily dose of possible substances will be applied to the blood sample. The percentage of dying cells allows to assess the efficacy of each substance.

Either common medications or alternative remedies can be tested.

Determination of the efficacy is possible even before the treatment starts.



Medication 2 shows the highest efficacy in this blood sample. The chance for a sustainable and successful therapy is increasing.



Example of a dying cell in the presence of a medication.

maintrac – therapy-relevant properties of the tumor cells


Are there any characteristics to determine an appropriate therapy?

A number of therapies should be only applied when the tumor cells comprise corresponding features. Especially in later stages of the treatment therapy-relevant properties of the tumor cells can change.


For example, this applies to the presence of important proteins, hormone receptors, immune regulators or HER2/neu amplification which play a role in breast cancer patients.

maintrac always considers the current situation of the patient.

With maintrac it is possible to characterize the currently present circulating tumor cells to find an appropriate therapy.



Circulating tumor cells expressing Ki67 (A), PD-L1 (B) or the estrogen receptor (C).




Circulating tumor cell that carries a HER2/neu amplification.


maintrac – maintenance therapy in breast and prostate cancer

Is the implementation and continuation of an endocrine therapy useful?

The continuation of an already 5 years lasting therapy is not always beneficial, i.e. with Tamoxifen. maintrac can assess whether the patient benefits from a prolonged treatment.



After the end of therapy, increasing CETCs are correlated with relapse.



A marginal change is usually a positive sign.

After finishing the therapy, increasing circulating tumor cells can lead to reinitiation of the therapy.

During the course of the disease the cell number will be tested repeatedly.

- Increasing cell numbers** = further diagnostics necessary and / or optimization of the therapy
- Constant cell numbers** = positive course of disease
- Decreasing cell numbers** = good prognosis / efficient therapy

Please talk about details and further procedures with the treating physician.